Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis

被引:10
|
作者
Castagnola, E
Davidson, RN
Fiore, P
Tasso, L
Rossi, G
Mangraviti, S
DiMartino, L
Scotti, S
Cascio, A
Pempinello, R
Gradoni, L
Giacchino, R
机构
[1] G GASLINI CHILDRENS HOSP,DEPT DIETET,I-16147 GENOA,ITALY
[2] G GASLINI CHILDRENS HOSP,LAB CLIN ANAL 1,I-16147 GENOA,ITALY
[3] NORTHWICK PK HOSP & CLIN RES CTR,LISTER INST INFECT & TROP DIS,LONDON,ENGLAND
[4] OSPED PAUSILLIPON,DEPT PAEDIAT 1,NAPLES,ITALY
[5] UNIV PALERMO,OSPED BAMBINI,DEPT INFECT DIS,PALERMO,ITALY
[6] PRESIDIO OSPED D COTUGNO,UNITA SANIT LOCALE 41,NAPLES,ITALY
[7] IST SUPER SANITA,PARASITOL LAB,I-00161 ROME,ITALY
关键词
leishmaniasis; Leishmania infantum; chemotherapy; liposomal amphotericin B; PINI score;
D O I
10.1016/S0035-9203(96)90270-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (Pwr), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.
引用
收藏
页码:317 / 318
页数:2
相关论文
共 50 条
  • [31] LIPOSOMAL AMPHOTERICIN-B IN DRUG-RESISTANT VISCERAL LEISHMANIASIS
    DAVIDSON, RN
    CROFT, SL
    SCOTT, A
    MAINI, M
    MOODY, AH
    BRYCESON, ADM
    LANCET, 1991, 337 (8749): : 1061 - 1062
  • [32] Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
    Sundar, Shyam
    Chakravarty, Jaya
    Agarwal, Dipti
    Rai, Madhukar
    Murray, Henry W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (06): : 504 - 512
  • [33] Liposomal amphotericin B for treatment of visceral leishmaniasis: results of a pilot study on 98 immunocompetent children
    DiMartino, L
    Castagnola, E
    Giacchino, R
    Tasso, L
    Scotti, S
    Raimondi, F
    Mantovani, MP
    Cascio, A
    Gradoni, L
    Scalone, A
    Davidson, RN
    RIVISTA ITALIANA DI PEDIATRIA-ITALIAN JOURNAL OF PEDIATRICS, 1997, 23 (02): : 241 - 244
  • [34] Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
    Russo, R
    Nigro, LC
    Minniti, S
    Montineri, A
    Gradoni, L
    Caldeira, L
    Davidson, RN
    JOURNAL OF INFECTION, 1996, 32 (02) : 133 - 137
  • [35] TREATMENT WITH LIPOSOMAL AMPHOTERICIN-B OF A CHILD AFFECTED WITH DRUG-RESISTANT VISCERAL LEISHMANIASIS
    GIACCHINO, R
    GIAMBARTOLOMEI, G
    TASSO, L
    TIMITILLI, A
    CASTAGNOLA, E
    BRISIGOTTI, M
    MICALIZZI, C
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1993, 87 (03) : 310 - 310
  • [36] A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience
    Cascio, A
    di Martino, L
    Occorsio, P
    Giacchino, R
    Catania, S
    Gigliotti, AR
    Aiassa, C
    Iaria, C
    Giordano, S
    Colomba, C
    Polara, VF
    Titone, L
    Gradoni, L
    Gramiccia, M
    Antinori, S
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) : 217 - 220
  • [37] US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
    Meyerhoff, A
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) : 42 - 48
  • [38] Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study
    Sundar, S
    Jha, TK
    Thakur, CP
    Mishra, M
    Singh, VP
    Buffels, R
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 800 - 804
  • [39] Comment on: Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
    Collazos, Julio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 466 - 467
  • [40] Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B
    Erat, Tugba
    An, Isa
    DERMATOLOGIC THERAPY, 2022, 35 (09)